Vitiligo: Concise evidence based guidelines on diagnosis and management

Postgraduate Medical Journal

Volumn 86, Issue 1018, 2010, Pages 466-471

  Gawkrodger, David J ^a   Ormerod, Anthony D ^a   Shaw, Lindsay ^b   Mauri Sole, Inma ^b   Whitton, Maxine E ^c   Watts, M Jane ^d   Anstey, Alex V ^a   Ingham, Jane ^e   Young, Katharine ^e  

^a BRITISH ASSOCIATION OF DERMATOLOGISTS   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c Vitiligo Society   (United Kingdom)

^d WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^e ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; COSMETIC; DEXAMETHASONE; FLUTICASONE PROPIONATE; MONOBENZONE; PIMECROLIMUS; STEROID; SUNSCREEN; TACROLIMUS;

ACNE; BURNING SENSATION; DEPIGMENTATION; DERMATOLOGY; DISTRESS SYNDROME; EVIDENCE BASED MEDICINE; HUMAN; HYPERTRICHOSIS; MENSTRUATION DISORDER; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRACTICE GUIDELINE; PUVA; REVIEW; SIDE EFFECT; SKIN ATROPHY; ULTRAVIOLET B RADIATION; VITILIGO; WEIGHT GAIN;

CALCINEURIN; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; PHOTOTHERAPY; PRACTICE GUIDELINES AS TOPIC; VITILIGO;

EID: 77956033426     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.093278     Document Type: Review

References (29)

1. Nordlund JJ, Majumder PP. Recent investigations on vitiligo vulgaris. Dermatologic Clinics 1997;15:69-78.
2. Mason CP, Gawkrodger DJ. Vitiligo presentation in adults. Clin Exper Dermatol 2005;30:344-5.
3. Nath SK, Majumder PP, Nordland JJ. Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated. Am J Hum Genet 1994;55:981-90.
4. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008;159:1051-76.
5. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, issue 1.
6. Firooz A, Bouzari N, Fallah N, et al. What patients with vitiligo believe about their condition. Int J Dermatol 2004;43:811-14. (Pubitemid 39529939)
7. Mattoo SK, Handa S, Kaur L, et al. Psychiatric morbidity in vitiligo: prevalence and correlates in India. J Eur Acad Dermatol Venerol 2002;16:573-8. (Pubitemid 35385745)
8. Ongenae K, Dierckxsens L, Brochez L, et al. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage, Dermatology 2005;210:279-85. (Pubitemid 40976734)
9. Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol 1999;72(Pt 3):385-96. (Pubitemid 29465543)
10. Stangier U, Gieler U, Ehlers A. Measuring adjustment to chronic skin disorders: validation of a self-report measure. Psychological Assessment 2003;15:532-49. (Pubitemid 37548972)
11. Bjoro T, Holmen J, Krüger O, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000;143:639-47.
12. Clayton R. A double-blind trial of 0-05% clobetasol proprionate in the treatment of vitiligo. Br J Dermatol 1977;96:71-3. (Pubitemid 8072502)
13. Kandil-E. Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol - a double-blind trial. Br J Dermatol 1974;91:457-60.
14. Westerhof W, Nieuweboer-Krobotova L, Mulder PGH, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999;135:1061-6.
15. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005;15:88-91. (Pubitemid 40434632)
16. Boone B, Ongenae K, Van Geel N, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007;17:55-61. Epub 2007 Feb 27.
17. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. [comment]. Arch Dermatol 2003;139:581-5.
18. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol 1977;97:669-79.
19. Radakovic FS, Furnsinn FA, Honigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001;44:814-17. (Pubitemid 32391170)
20. Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatol Treat 2006;17:151-3. (Pubitemid 44147831)
21. Yones SS, Palmer RA, Garibaldinos TM, et al. Randomised double-blind trial of treatment of vitiligo. Efficacy of Psoralen-UVA vs. narrowband-UVB therapy. Arch Dermatol 2007;143:578-84.
22. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical Psoralen plus UVA. Arch Dermatol 1997;133:1525-8.
23. Njoo MD, Westerhoff W, Bos JD, et al. A systematic review of autologous transplantation methods in vitiligo Arch Dermatol 1998;134:1543-9.
24. Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995;190:223-9.
25. Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 2009;161:910-17. Epub 2009 Jun 11.
26. Papadopoulos L, Bor R, Legg C. Psychological factors in cutaneous disease; an overview of research. Psychol Health Med 1999;4:107-26. (Pubitemid 29237923)
27. Thomson AR, Kent G, Smith JA. Living with vitiligo: dealing with difference. Br J Health Psychol 2002;7:213-25.
28. Birlea SA, Gowan K, Fain PR, et al. Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. J Invest Dermatol 2010;130:798-803. Epub 2009 Nov 5.
29. Waterman EA, Gawkrodger DJ, Watson PF, et al. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. J Invest Dermatol 2010;130:230-40.